ciltacabtagene autoleucel + talquetamab

This is a **combination therapy** consisting of two highly advanced immunotherapeutic agents for **multiple myeloma**: - **Ciltacabtagene autoleucel (Carvykti)** is a **BCMA-directed autologous CAR-T cell therapy**. It works by genetically modifying a patient's own T cells to express a chimeric antigen receptor (CAR) specific for B-cell maturation antigen (BCMA), which is highly expressed on multiple myeloma cells. The CAR-T cells are then reinfused into the patient to recognize and kill BCMA-expressing myeloma cells. - **Talquetamab (Talvey)** is a **bispecific monoclonal antibody (T-cell engager)** targeting **GPRC5D** on multiple myeloma cells and CD3 on T cells, redirecting T cells to engage and eliminate myeloma cells expressing GPRC5D. The combination is under clinical investigation for use in patients with relapsed/refractory or high-risk multiple myeloma. The rationale is to simultaneously target two distinct antigens on myeloma cells to improve efficacy, deepen responses, and potentially overcome resistance observed with single-agent therapies[3].

Other names

cilta-cel + talquetamabJNJ-68284528 + JNJ-64407564